India-based Glenmark has signed a supply and marketing agreement with Aspen USA for joint manufacturing and sales of three generic products in U.S. The three generic solid-dose formulations are in the pain management/therapeutic segment, said Glenmark. As per the agreement Aspen will supply the products to Glenmark, which will market them under the Glenmark label.
Glenmark will make an undisclosed initial milestone payment to Aspen for the exclusive marketing rights to the products and the two parties will share the profits on net sales in the U.S. market.
"It will significantly add to the six products that we currently have in the U.S. and will go a long way in strengthening our generic presence there," said Glenn Saldanha, Glenmark's managing director and CEO.